Abstract: In accordance with some embodiments, a package-on-package (PoP) structure includes a first semiconductor package having a first side and a second side opposing the first side, a second semiconductor package having a first side and a second side opposing the first side, and a plurality of inter-package connector coupled between the first side of the first semiconductor package and the first side of the second semiconductor package. The PoP structure further includes a first molding material on the second side of the first semiconductor package. The second side of the second semiconductor package is substantially free of the first molding material.

Abstract: Interconnect structure packages (e.g., through silicon vias (TSV) packages, through interlayer via (TIV) packages) may be pre-manufactured as opposed to forming TIVs directly on a carrier substrate during a manufacturing process for a semiconductor die package at backend packaging facility. The interconnect structure packages may be placed onto a carrier substrate during manufacturing of a semiconductor device package, and a semiconductor die package may be placed on the carrier substrate adjacent to the interconnect structure packages. A molding compound layer may be formed around and in between the interconnect structure packages and the semiconductor die package.

Abstract: A memory device including a base semiconductor die, conductive terminals, memory dies, an insulating encapsulation and a buffer cap is provided. The conductive terminals are disposed on a first surface of the base semiconductor die. The memory dies are stacked over a second surface of the base semiconductor die, and the second surface of the base semiconductor die is opposite to the first surface of the base semiconductor die. The insulating encapsulation is disposed on the second surface of the base semiconductor die and laterally encapsulates the memory dies. The buffer cap covers the first surface of the base semiconductor die, sidewalls of the base semiconductor die and sidewalls of the insulating encapsulation. A package structure including the above-mentioned memory device is also provided.

Abstract: A memory device including a base semiconductor die, conductive terminals, memory dies, an insulating encapsulation and a buffer cap is provided. The conductive terminals are disposed on a first surface of the base semiconductor die. The memory dies are stacked over a second surface of the base semiconductor die, and the second surface of the base semiconductor die is opposite to the first surface of the base semiconductor die. The insulating encapsulation is disposed on the second surface of the base semiconductor die and laterally encapsulates the memory dies. The buffer cap covers the first surface of the base semiconductor die, sidewalls of the base semiconductor die and sidewalls of the insulating encapsulation. A package structure including the above- mentioned memory device is also provided.

Abstract: The present disclosure provides compositions and dosage forms comprising sinetirucallol, and methods of using such compositions, such as to treat an inflammation-associated disease, liver fibrosis, wound healing, and/or an autoimmune disease. In some embodiments, the composition comprises a Spiranthes sinensis extract.

Abstract: The present disclosure provides compositions and dosage forms comprising sinetirucallol, and methods of using such compositions, such as to treat an inflammation-associated disease, liver fibrosis, wound healing, and/or an autoimmune disease. In some embodiments, the composition comprises a Spiranthes sinensis extract.

Abstract: The present disclosure provides compositions and dosage forms comprising sinetirucallol, and methods of using such compositions, such as to treat an inflammation-associated disease, liver fibrosis, wound healing, and/or an autoimmune disease. In some embodiments, the composition comprises a Spiranthes sinensis extract.

Abstract: The present invention is related to a pharmaceutical composition comprising an effective amount of a Spiranthes sinensis extract and a pharmaceutically acceptable carrier. The present invention improves the economic value of Spiranthes sinensis by verifying the efficacies of said pharmaceutical composition in anti-inflammation, anti-liver fibrosis and/or anti-oxidation.

Abstract: The present invention provides a novel formulation for cancer treatment and a method for enhancing the HCD's efficacy in cancer treatment. Specifically, the present invention provides copper-modified silica nanoparticles loaded with HCD, which exhibits better efficacy than some conventional anticancer drugs.

Abstract: The present invention relates to a method or composition for treating diabetes mellitus, comprising administering a subject with a pharmaceutical composition comprising a therapeutically effective amount of an active compound from Antrodia camphorate, such as antroquinonols, and a pharmaceutically acceptable carrier. In addition, the prevent invention provides a new process for the total synthesis of antroquinonol. Also provided are the new compounds produced during the process for preparing of antroquinonol.

Abstract: The present invention provides a novel formulation for cancer treatment and a method for enhancing the HCD's efficacy in cancer treatment. Specifically, the present invention provides copper-modified silica nanoparticles loaded with HCD, which exhibits better efficacy than some conventional anticancer drugs.

Abstract: The present invention provides a pharmaceutical composition for wound healing and/or skin whitening. The pharmaceutical composition comprises active ingredient of Andrographis paniculata extract and/or Andrographolide and a pharmaceutical acceptable carrier. The present invention also provides a method for wound healing and/or skin whitening by using the present pharmaceutical composition. The composition and method of the present invention show better efficacy in wound healing and skin whitening than conventional drugs.

Abstract: The present invention relates to a method or composition for glycemic control in a subject, which is effective for treating diabetes mellitus, comprising administering the subject with a pharmaceutical composition comprising a therapeutically effective amount of an aliphatic alcohol having a general formula of CH3(CH2)nCH2OH, wherein n is an integer from 10 to 40, such as tetracosanol, and a pharmaceutically acceptable carrier.

Abstract: The present invention is related to a method and pharmaceutical composition for treating colorectal cancer. The pharmaceutical composition comprises an effective amount of 16-hydroxy-cleroda-3,13-dine-15,16-olide as active ingredient, and a pharmaceutically acceptable carrier. The present method and pharmaceutical composition provides good efficacy in treating colorectal cancer. The present invention also establishes an animal model, which provides a better drug screening platform for the research.

Abstract: The present invention is related to a method and pharmaceutical composition for treating lung cancer. The pharmaceutical composition comprises an effective amount of 16-hydroxy-cleroda-3,13-dine-15,16-olide as active ingredient, and a pharmaceutically acceptable carrier. The present method and pharmaceutical composition provides good efficacy in treating lung cancer even for drug-resistance patient. The present invention also establishes an animal model bearing human lung cancer, which provides a better drug screening platform for the research.

Abstract: The present invention is related to a pharmaceutical composition comprising an effective amount of a Spiranthes sinensis extract and a pharmaceutically acceptable carrier. The present invention improves the economic value of Spiranthes sinensis by verifying the efficacies of said pharmaceutical composition in anti-inflammation, anti-liver fibrosis and/or anti-oxidation.

Abstract: The present invention relates to a method or composition for treating diabetes mellitus, comprising administering a subject with a pharmaceutical composition comprising a therapeutically effective amount of an active compound from Antrodia camphorate, such as antroquinonols, and a pharmaceutically acceptable carrier. In addition, the prevent invention provides a new process for the total synthesis of antroquinonol. Also provided are the new compounds produced during the process for preparing of antroquinonol.

Abstract: The present invention provides a pharmaceutical composition for wound healing and/or skin whitening. The pharmaceutical composition comprises active ingredient of Andrographis paniculata extract and/or Andrographolide and a pharmaceutical acceptable carrier. The present invention also provides a method for wound healing and/or skin whitening by using the present pharmaceutical composition. The composition and method of the present invention show better efficacy in wound healing and skin whitening than conventional drugs.

Abstract: The present invention is related to a method for liver fibrosis prevention and/or treatment and a pharmaceutical composition thereof. The method and the pharmaceutical composition are made by taking the advantage of Blumea lacera ‘efficacy in accumulating lipid in hepatic stellate cells, down-regulating the proliferation of hepatic stellate cells, inhibiting the mobility of hepatic stellate cells, preventing the activation of hepatic stellate cells, and decreasing the synthesis of ECM proteins. The present invention not only provides a novel optional for clinical prevention and treatment of liver fibrosis, but also promotes the industrial value of Blumea lacera.

Abstract: The present invention relates to a method or composition for glycemic control in a subject, which is effective for treating diabetes mellitus, comprising administering the subject with a pharmaceutical composition comprising a therapeutically effective amount of an aliphatic alcohol having a general formula of CH3(CH2)nCH2OH, wherein n is an integer from 10 to 40, such as tetracosanol, and a pharmaceutically acceptable carrier.